Compare AMBQ & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBQ | ZVRA |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 653.2M |
| IPO Year | N/A | 2015 |
| Metric | AMBQ | ZVRA |
|---|---|---|
| Price | $80.28 | $10.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $42.20 | $23.00 |
| AVG Volume (30 Days) | 876.5K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $41.81 | $37.27 |
| Revenue Next Year | $27.98 | $53.42 |
| P/E Ratio | ★ N/A | $18.13 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $22.12 | $7.16 |
| 52 Week High | $85.72 | $13.16 |
| Indicator | AMBQ | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 70.86 | 52.37 |
| Support Level | $25.90 | $8.26 |
| Resistance Level | $85.72 | $11.07 |
| Average True Range (ATR) | 5.98 | 0.56 |
| MACD | -0.34 | 0.00 |
| Stochastic Oscillator | 74.59 | 42.30 |
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.